Exercise of Options

RNS Number : 5545W

Creo Medical Group PLC

23 December 2021

 

 Creo Medical Group plc

("Creo" or the "Company")

Exercise of Options

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, confirms that it has issued, conditional on admission, 90,000 new ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares"), pursuant to the exercise of share options. It is expected that admission of the Ordinary Shares will occur at 8:00 a.m. on 31 December 2021.

Following admission, the Company will have 181,009,186 Ordinary Shares in issue. This figure of 181,099,186 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure and Transparency Rules.

Enquiries:

Creo Medical Group plc	www.creomedical.com
Richard Rees (CFO)	[phone]
Cenkos Securities plc	[phone]
Stephen Keys / Camilla Hume (NOMAD)
Michael Johnson / Russell Kerr (Joint Broker)
Numis Securities Limited (Joint Broker)	[phone]
Freddie Barnfield / James Black / Duncan Monteith
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus / Sam Allen / Phillip Marriage	Mob: [phone]

About Creo Medical  

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.  

For more information about Creo Medical please see our website, www.creomedical.com

 

END

 

 

MSCGZMZZLZMGMZM